My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Solid Biosciences Inc. - Common Stock (NQ:SLDB)

5.730 +0.540 (+10.40%)

Streaming Delayed Price Updated: 3:07 PM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Solid Biosciences Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results

December 03, 2025

December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an...

Via MarketMinute

Xpeng, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 17, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 04, 2025

Via Benzinga

Fed Trims Rates by 0.25%: A New Era of Dovish Policy and Portfolio Rebalancing

September 17, 2025

The Federal Reserve has announced a 0.25% reduction in its benchmark interest rate, marking a significant shift towards a more accommodative monetary policy. This move, while seemingly modest, carries...

Via MarketMinute

Federal Reserve Poised for September Rate Cut Amidst High Market Expectations and Powell's Jackson Hole Address

August 19, 2025

Investor sentiment is overwhelmingly pointing towards a significant shift in the Federal Reserve's monetary policy, with a near-certainty of a 25-basis-point interest rate cut anticipated at its...

Via MarketMinute

Topics Bonds Credit Cards Economy

Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside ↗

August 12, 2025

Per two Wall Street analysts, one of 2025's biggest losers could be set up for a stunning recovery. They see over 175% upside in Sarepta Therapeutics.

Via MarketBeat

Topics Death

Solid Biosciences Stock Pops On US, Canada Nod For Gene Therapy Trials: Retail Buzz Spikes ↗

July 09, 2025

The company plans to begin a Phase 1b trial of SGT-501 later this year, targeting CPVT, a rare and potentially fatal arrhythmia in children and young adults with no current FDA-approved therapies.

Via Stocktwits

Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand ↗

June 20, 2025

Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenue prospects.

Via Benzinga

Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences

June 18, 2025

After a second patient passed away, Sarepta Therapeutics crashed. Solid Biosciences rose over 10% in response. Wall Street sees big upside in both names.

Via MarketBeat

Topics Earnings

Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

June 16, 2025

Via Benzinga

Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket ↗

June 16, 2025

Via Benzinga

Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation ↗

May 07, 2025

FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.

Via Benzinga

Can Solid Biosciences Challenge Sarepta in the DMD Market?

April 08, 2025

Solid Biosciences' Duchenne muscular dystrophy (DMD) drug could provide superior outcomes compared to an already approved medication projected to make billions.

Via MarketBeat

Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week ↗

February 23, 2025

Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.

Via Stocktwits

Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?

February 19, 2025

Solid Biosciences just saw a 32% move to the upside after its trial results impressed. What's next for this firm that analysts still see massive potential in?

Via MarketBeat

Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move? ↗

February 18, 2025

Early-stage data from the company's gene therapy candidate SGT-003 for Duchenne muscular dystrophy (DMD) showed encouraging results.

Via Stocktwits

Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data ↗

February 18, 2025

Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.

Via Benzinga

Stocks Quiet As S&P 500 Nears All-Time High ↗

February 18, 2025

All three major indexes are fresh off weekly wins.

Via Talk Markets

Topics Stocks Stocks / Equities

Tuesday's session: gap up and gap down stocks ↗

February 18, 2025

In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

February 18, 2025

The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

February 10, 2025

Via Benzinga

Why BP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket ↗

February 10, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 10, 2025

Via Benzinga

Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development ↗

January 08, 2025

Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting key 2025 milestones.

Via Benzinga

Why Cal-Maine Foods Shares Are Trading Higher By 4%; Here Are 20 Stocks Moving Premarket ↗

January 08, 2025

Via Benzinga

Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst ↗

December 13, 2024

Wedbush initiates Solid Biosciences with an Outperform rating, citing the potential of SGT-003 for Duchenne muscular dystrophy and a robust cash runway.

Via Benzinga

iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

September 16, 2024

Via Benzinga

SLDB Stock Earnings: Solid Biosciences Beats EPS for Q2 2024 ↗

August 13, 2024

SLDB stock results show that Solid Biosciences beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

This Planet Fitness Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗

June 24, 2024

Via Benzinga

Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket ↗

June 21, 2024

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.